BMRA News and Press, Biomerica Inc. From 05/12/22

- Attaining CE Mark is a major step toward commercialization – - World Health Organization (WHO) lists H. pylori among the 16 antibiotic-resistant bacteria that pose the greatest threat to human health and designated H. pylori as a Class 1 carcinogen...

Biomerica (NASDAQ:BMRA) submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for hp+detect test that detects the presence of Helicobacter pylori (H. pylori) bacteria. The company said that over 80% of gastric cancers are attributed to H. pylo...

Gastric cancer is the third most common cause of cancer related death in the world and over 80% of gastric cancers are attributed to H. pylori bacterial infection H. pylori infection is also a major cause of peptic ulcers IRVINE, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- ...

Biomerica press release (NASDAQ:BMRA): Q3 GAAP EPS of -$0.01. Revenue of $7.6M (+111.1% Y/Y). For further details see: Biomerica GAAP EPS of -$0.01, revenue of $7.6M

Q3 Net loss per share of $0.01 vs. a net loss of $0.18 per share from same period last year InFoods® IBS diagnostic-guided therapy clinical trial results demonstrated statistically significant improvement in multiple symptom related endpoints including Abdominal Pain Intens...

Biomerica Inc. (NASDAQ:BMRA) traded today at a new 52-week high of $23.38. This new high was reached on above average trading volume as 46.2 million shares traded hands, while the average 30-day volume is approximately 40,000 shares. Biomerica Inc is engaged in the development, manufactu...

Biomerica (NASDAQ:BMRA) reported positive results from trial of its test, InFoods IBS diagnostic-guided therapy (DGT) in patients with Irritable Bowel Syndrome (IBS). The InFoods DGT for IBS uses a simple blood test designed to identify patient-specific foods that when removed from the d...

InFoods® IBS Diagnostic-Guided Therapy is the first therapy of its kind using science, diet and technology to identify patient specific foods, which when eliminated, help reduce the symptoms of IBS without the use of drugs Multiple endpoints demonstrated statistically ...

Revenues up 239% over prior year fiscal second quarter Customer orders backlog of over $4.0 million at November 30, 2021 Walmart began in-store and online sales of Biomerica’s EZ Detect™ Colon Disease Test during fiscal second quarter InFoods ...

Biomercia (NASDAQ:BMRA) is up 12% in pre-market trading after the company reported 238% revenue growth in its Q2 preliminary earnings report. Revenue made a easy beat at $4.6M (+238% Y/Y), compared to the market consensus of $1.81M. The increase reflects the surge in demand for Covi...